

MAR 14 2007

FAX NO.: 571/273-8300

Atty Docket No. 160 US UT01

**OFFICIAL COMMUNICATION FOR THE ATTENTION OF
THE U.S. PATENT AND TRADEMARK OFFICE**

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents in re Application of Law et al., Application No. 10/741,657, filed December 19, 2003, for ANTIBODIES AGAINST GPR64 AND USES THEREOF are being facsimile transmitted to the United States Patent and Trademark Office, on the date shown below.

Documents Attached

1. Transmittal Form (1 page)
2. Amendment and Response (16 pages)

Number of pages being transmitted, including this page: 17

Dated: March 14, 2007

Linda Pete
Linda Pete

*PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (510) 574-1473*

PDL BIOPHARMA, INC.
Legal Department
34801 Campus Drive
Fremont, CA 94555
Telephone: 510/574-1400
Customer No.: 47470

MAR 14 2007

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

		Application Number	10/741,657
		Filing Date	December 19, 2003
		First Named Inventor	Debbie Law, et al.
		Art Unit	1643
		Examiner Name	Rawlings, Stephen L.
Total Number of Pages in This Submission	16	Attorney Docket Number	160 US UT01

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request(SB/22)	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

The Director is hereby authorized to charge any fee(s) or underpayments of fee(s) or credit any overpayments to PDL BioPharma, Inc. Deposit Account No. 50-3270 for the paper(s) submitted herewith.

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual name	Susan Harlocker, No. 59,144, PDL BioPharma, Inc.		
Signature			
Date	March 14, 2007		

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO (Facsimile No. 571-273-8300) or deposited with the United States Postal Service with sufficient postage as Express mail (Label No.) in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 14, 2007.

Typed or printed name	Linda Pete		
Signature		Date	March 14, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MAR 14 2007

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1643 :
Examiner: Rawlings, Stephen L. :
In re Application of: : ANTIBODIES AGAINST
Debbie Law, *et al.* : GPR64 AND USES THEREOF
Serial No.: 10/741,657 :
Filing Date: December 19, 2003 :
Attorney Docket No.: 160 US UT01 :
Customer No.: 47470 : Confirmation No.: 6189

AMENDMENT AND RESPONSE

Fremont, CA 94555
March 14, 2007

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sirs:

This is a response to the Office Action in the above-referenced application dated December 18, 2006, having a shortened statutory period set to expire March 18, 2007.

Please amend the application captioned above as follows.